BMA
Banco Macro S.A.
There isn't enough reported data to score BMA yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
BMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| N/A | |
| N/A |
BMA's profitability is currently stable. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like BMA.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
BMA PE Valuation
BMA has no meaningful PE right now: it lost money over the past year.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
BMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for BMA, with profitability improving.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
BMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | $2.98 | -59% |
| Q2 2025 | $4.23 | -35% |
| Q1 2025 | -$0.48 | -104% |
| Q4 2024 | $3.45 | -51% |
| Q3 2024 | $7.21 | +226% |
| Q2 2024 | $6.52 | +198% |
| Q1 2024 | $11.38 | +1735% |
| Q4 2023 | $7.10 | +1009% |
MS has the stronger earnings trend. Trailing diluted EPS is down 59% for BMA versus MS up 29%.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS's earnings per share have climbed steadily: $12.60 over the past year, up 29% from the year before, and higher year over year for 10 quarters in a row.
BMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $950.1M | +4.1% |
| Q1 2026 | $1.2B | +70% |
| Q3 2025 | $933.9M | +30% |
| Q2 2025 | $912.7M | +16% |
| Q1 2025 | $725M | -66% |
| Q4 2024 | $970.7M | -44% |
| Q3 2024 | $719.9M | -46% |
| Q2 2024 | $789.5M | -29% |
BMA has the stronger quarterly revenue trend. Revenue is up 31% for BMA versus up 12% for MS.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 22% | +15 points |
| Q1 2026 | 11% | -0.1 points |
| Q3 2025 | -2.6% | -14 points |
| Q2 2025 | 17% | +59 points |
| Q1 2025 | 7.2% | -10 points |
| Q4 2024 | 11% | -17 points |
| Q3 2024 | 11% | +8 points |
| Q2 2024 | -41% | -55 points |
BMA's operating margin was 22% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over BMA on profitability, with a higher operating margin.
BMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $372.3M | +$984.4M |
| Q1 2026 | $384.5M | +$1B |
| Q3 2025 | $304.5M | -63% |
| Q2 2025 | -$612.1M | -271% |
| Q1 2025 | -$616.8M | -10886964% |
| Q4 2024 | -$353.2M | -$232.5M |
| Q3 2024 | $818.8M | +$896.2M |
| Q2 2024 | $357M | +$365.4M |
BMA has the stronger cash trend. Its trailing FCF is up 207% versus its history, compared with MS at down 492%.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
BMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -38K shares |
| 1 year | -0.1% | -40.3K shares |
| 3 years | -0.1% | -40.3K shares |
| 5 years | -1.2% | -804K shares |
| Available history | -0.1% | -38.8K shares |
BMA has 64M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over BMA on shareholder dilution, with a more favorable share count trend.
BMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -3.1x | Net Cash |
| Q2 2025 | -2.0x | Net Cash |
| Q1 2025 | -57.5x | Net Cash |
| Q4 2024 | -4.4x | Net Cash |
| Q3 2024 | -2.8x | Net Cash |
| Q2 2024 | -1.3x | Net Cash |
| Q1 2024 | -0.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
BMA has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BMA.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
BMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 4.0 | Oversold |
BMA's weekly RSI is 33 (neutral) and its Stochastic is 4 (oversold).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
BMA PE vs Financial Services Sector
BMA has no meaningful PE right now: it lost money over the past year.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
BMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.7 | 12% below |
| 20 week MA | $75.0 | 26% below |
| 50 week MA | $80.5 | 31% below |
| 100 week MA | $79.3 | 30% below |
| 200 week MA | $59.4 | 6.9% below |
BMA is in a downtrend: it's below all five of its weekly moving averages, and 6.9% below its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over BMA on trend strength, trading above more of its moving averages.
BMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.4 | $15.6 | -57% |
| 2021 | $15.6 | $14.6 | -6.6% |
| 2022 | $14.6 | $15.8 | +8.9% |
| 2023 | $15.8 | $28.7 | +81% |
| 2024 | $28.7 | $100.2 | +249% |
| 2025 | $100.2 | $91.4 | -8.8% |
| 2026 YTD | $91.4 | $55.2 | -40% |
BMA's yearly returns have swung widely, from +249% in 2024 to −57% in 2020. It's down 40% so far in 2026.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over BMA on returns for 2026, with the stronger performance.